@RNAiAnalyst How important do you think it is for a #COVIDvaccine to demonstrate non-inferiority (if not superiority) to the front-runner (i.e., $PFE / $BNTX) versus simply meeting the FDA threshold, given the fact that there will be significant room for multiple vaccines on the market?